Bipartisan Legislation Seeks Medicare Coverage for FDA-Cleared Alzheimer's Tests

Members of Congress from both parties have introduced the ASAP Act, bipartisan and bicameral legislation aimed at authorizing the Secretary of Health and Human Services to establish a pathway for Medicare coverage of FDA-approved or cleared blood-based biomarker tests for the early detection of Alzheimer's disease and other dementias. The initiative seeks to broaden access to early diagnosis and treatment, addressing the significant financial and personal burdens of late-stage Alzheimer's care.